Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

This collaboration builds on the foundation of earlier work performed by GATC for Lisata, in which GATC provided AI-derived analysis in support of Lisata's certepetide drug candidate. Under the expanded relationship, Lisata will enhance its therapeutic pipeline by leveraging GATC's proprietary Multiomics Advanced Technology® (MAT) platform to identify new AI-predicted combination therapies (including with certepetide) across all therapeutic areas. This approach not only opens the door to new treatment possi ...